Bristol-Myers Squibb Co., the global biopharmaceutical company, said Thursday that it will launch a $250 million expansion of its manufacturing complex in Devens and nearly double the size of its workforce there.
The expansion will add space for developing biotechnology drugs, called biologics, and for manufacturing those products for clinical trials, a requirement of the drug approval process. Read the full story.